-
Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a single-center, randomized, double-blind, placebo-controlled, dosage escalation Phase Ia study. The study will assess the safety, tolerability, and pharmacokinetics of G201-Na in healthy adult males in China. G201-Na: A Small…
-
Mabwell’s 9MW2821 ADC Shows Positive Signals in Solid Tumor Clinical Data
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced preliminary clinical data for its antibody-drug conjugate (ADC) 9MW2821, which targets Nectin-4. The data demonstrated positive therapeutic signals in multiple solid tumors and exhibited a good safety profile at the recommended Phase II dosage (RP2D). Mechanism of Action and Pharmaceutical…
-
Gates Foundation and NSFC Launch Partnership to Boost Regulatory Science in Vaccine Development
•
The Bill & Melinda Gates Foundation (Gates Foundation) and the National Natural Science Foundation of China (NSFC) have unveiled a strategic partnership aimed at enhancing regulatory science, with a particular focus on vaccine development. This joint program will invite research proposals centered on new regulatory science systems, tools, and methodologies,…
-
AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital
•
AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and SIFI S.p.A.—has announced the first patient enrollment in a clinical study for its AMD201 at the Beijing Tiantan Hospital. This marks a significant step in the development of digital therapies for post-stroke cognitive impairment (PSCI).…
-
Provincial Budgets Highlight Top Earning Hospitals in China for 2023
•
Provincial governments have revealed the budget for provincial hospitals’ expected income during 2023, offering a glimpse into the financial landscape of China’s healthcare sector. Among the highest-ranking hospitals are The First Affiliated Hospital of Zhengzhou University, Tongji Hospital, and the First Affiliated Hospital, College of Medicine, Zhejiang University. The First…
-
Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan
•
Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal spray has been approved by the Hainan Medical Products Administration as a clinically urgently needed import drug in Bo’ao Super Hospital. This marks a significant milestone as the product is the world’s first and only…
-
Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with Belgium-based ExeVir Bio. The collaboration aims to explore the infectious disease sector, with no financial details or other specifics disclosed at this time. ExeVir Bio’s Nanoantibody-Based Therapy PlatformExeVir Bio is a clinical biotechnology…
-
AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role
•
Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV), has decided to leave his post, according to an internal email. Intercon’s Senior Vice President Alberto Colzi will step in to take over temporarily until a successor is appointed. Ou Silang’s Tenure and BackgroundOu Silang…
